Literature DB >> 23359252

β1 integrins mediate resistance to ionizing radiation in vivo by inhibiting c-Jun amino terminal kinase 1.

Hira Lal Goel1, Aejaz Sayeed, Michael Breen, Matthew J Zarif, David S Garlick, Irwin Leav, Roger J Davis, Thomas J Fitzgerald, Andrea Morrione, Chung-Cheng Hsieh, Qin Liu, Adam P Dicker, Dario C Altieri, Lucia R Languino.   

Abstract

This study was carried out to dissect the mechanism by which β1 integrins promote resistance to radiation. For this purpose, we conditionally ablated β1 integrins in the prostatic epithelium of transgenic adenocarcinoma of mouse prostate (TRAMP) mice. The ability of β1 to promote resistance to radiation was also analyzed by using an inhibitory antibody to β1 , AIIB2, in a xenograft model. The role of β1 integrins and of a β1 downstream target, c-Jun amino-terminal kinase 1 (JNK1), in regulating radiation-induced apoptosis in vivo and in vitro was studied. We show that β1 integrins promote prostate cancer (PrCa) progression and resistance to radiation in vivo. Mechanistically, β1 integrins are shown here to suppress activation of JNK1 and, consequently apoptosis, in response to irradiation. Downregulation of JNK1 is necessary to preserve the effect of β1 on resistance to radiation in vitro and in vivo. Finally, given the established crosstalk between β1 integrins and type1 insulin-like growth factor receptor (IGF-IR), we analyzed the ability of IGF-IR to modulate β1 integrin levels. We report that IGF-IR regulates the expression of β1 integrins, which in turn confer resistance to radiation in PrCa cells. In conclusion, this study demonstrates that β1 integrins mediate resistance to ionizing radiation through inhibition of JNK1 activation.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23359252      PMCID: PMC3749928          DOI: 10.1002/jcp.24323

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  52 in total

Review 1.  The IGF-1 receptor in cancer biology.

Authors:  Renato Baserga; Francesca Peruzzi; Krysztof Reiss
Journal:  Int J Cancer       Date:  2003-12-20       Impact factor: 7.396

2.  A cytoplasmic inhibitor of the JNK signal transduction pathway.

Authors:  M Dickens; J S Rogers; J Cavanagh; A Raitano; Z Xia; J R Halpern; M E Greenberg; C L Sawyers; R J Davis
Journal:  Science       Date:  1997-08-01       Impact factor: 47.728

3.  Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.

Authors:  Kazuki N Sugahara; Tambet Teesalu; Priya Prakash Karmali; Venkata Ramana Kotamraju; Lilach Agemy; Daniel R Greenwald; Erkki Ruoslahti
Journal:  Science       Date:  2010-04-08       Impact factor: 47.728

4.  Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model.

Authors:  Kristen Bisanz; Jie Yu; Magnus Edlund; Bill Spohn; Mien-Chie Hung; Leland W K Chung; Chia-Ling Hsieh
Journal:  Mol Ther       Date:  2005-10       Impact factor: 11.454

5.  Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study.

Authors:  Alejandro D Ricart; Anthony W Tolcher; Glenn Liu; Kyle Holen; Garry Schwartz; Mark Albertini; Geoffrey Weiss; Salim Yazji; Chee Ng; George Wilding
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

Review 6.  Role of mitogen-activated protein kinase kinase 4 in cancer.

Authors:  A J Whitmarsh; R J Davis
Journal:  Oncogene       Date:  2007-05-14       Impact factor: 9.867

7.  AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts.

Authors:  Jing Zhang; Serk In Park; Marlene C Artime; Justin M Summy; Ami N Shah; Joshua A Bomser; Andrea Dorfleutner; Daniel C Flynn; Gary E Gallick
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

8.  Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts.

Authors:  Catherine C Park; Hui J Zhang; Evelyn S Yao; Chong J Park; Mina J Bissell
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

9.  Increased tumor cell dissemination and cellular senescence in the absence of beta1-integrin function.

Authors:  Angelika Kren; Vanessa Baeriswyl; François Lehembre; Christoph Wunderlin; Karin Strittmatter; Helena Antoniadis; Reinhard Fässler; Ugo Cavallaro; Gerhard Christofori
Journal:  EMBO J       Date:  2007-05-31       Impact factor: 11.598

10.  β1 integrin deletion enhances progression of prostate cancer in the TRAMP mouse model.

Authors:  Kim Moran-Jones; Anita Ledger; Matthew J Naylor
Journal:  Sci Rep       Date:  2012-07-24       Impact factor: 4.379

View more
  29 in total

Review 1.  Concise Review: Prostate Cancer Stem Cells: Current Understanding.

Authors:  Sergej Skvortsov; Ira-Ida Skvortsova; Dean G Tang; Anna Dubrovska
Journal:  Stem Cells       Date:  2018-08-27       Impact factor: 6.277

2.  αvβ3 Integrin Mediates Radioresistance of Prostate Cancer Cells through Regulation of Survivin.

Authors:  Tao Wang; Jiayi Huang; Mai Vue; Michael R Alavian; Hira Lal Goel; Dario C Altieri; Lucia R Languino; Thomas J FitzGerald
Journal:  Mol Cancer Res       Date:  2018-09-28       Impact factor: 5.852

3.  AIF promotes a JNK1-mediated cadherin switch independently of respiratory chain stabilization.

Authors:  Andrew J Scott; Sierra A Walker; Joshua J Krank; Amanda S Wilkinson; Kaitlyn M Johnson; Eric M Lewis; John C Wilkinson
Journal:  J Biol Chem       Date:  2018-08-09       Impact factor: 5.157

Review 4.  Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy.

Authors:  Jennifer Wu; Evan Yu
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

5.  RAD9 enhances radioresistance of human prostate cancer cells through regulation of ITGB1 protein levels.

Authors:  Constantinos G Broustas; Howard B Lieberman
Journal:  Prostate       Date:  2014-08-11       Impact factor: 4.104

6.  c-Src, Insulin-Like Growth Factor I Receptor, G-Protein-Coupled Receptor Kinases and Focal Adhesion Kinase are Enriched Into Prostate Cancer Cell Exosomes.

Authors:  Rachel M DeRita; Brad Zerlanko; Amrita Singh; Huimin Lu; Renato V Iozzo; Jeffrey L Benovic; Lucia R Languino
Journal:  J Cell Biochem       Date:  2016-07-12       Impact factor: 4.429

7.  PSMA redirects cell survival signaling from the MAPK to the PI3K-AKT pathways to promote the progression of prostate cancer.

Authors:  Leslie Ann Caromile; Kristina Dortche; M Mamunur Rahman; Christina L Grant; Christopher Stoddard; Fernando A Ferrer; Linda H Shapiro
Journal:  Sci Signal       Date:  2017-03-14       Impact factor: 8.192

Review 8.  Microenvironmental regulation of therapeutic response in cancer.

Authors:  Florian Klemm; Johanna A Joyce
Journal:  Trends Cell Biol       Date:  2014-12-22       Impact factor: 20.808

Review 9.  The insulin-like growth factor-I receptor (IGF-IR) in breast cancer: biology and treatment strategies.

Authors:  Morteza Motallebnezhad; Leili Aghebati-Maleki; Farhad Jadidi-Niaragh; Hamid Nickho; Hosein Samadi-Kafil; Karim Shamsasenjan; Mehdi Yousefi
Journal:  Tumour Biol       Date:  2016-07-21

10.  Insulin-like growth factor-1 receptor expression in upper tract urothelial carcinoma.

Authors:  Marie-Lisa Eich; Aline C Tregnago; Sheila F Faraj; Doreen N Palsgrove; Kazutoshi Fujita; Stephania M Bezerra; Enrico Munari; Rajni Sharma; Alcides Chaux; George J Netto
Journal:  Virchows Arch       Date:  2018-10-18       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.